=Dupixent : FDA approves 1st drug for moderate & severe eczema

• The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) Injection, an interleukin-4 receptor alpha antagonist indicated for the treatment of adults with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable.

The Food and Drug Administration approved a new drug on Tuesday to treat serious cases of eczema.

The drug, called Dupixent, is a twice-a-month injection under the skin. Patients can do it at home. It'll cost $37,000 a year but the drug's makers, Regeneron Pharmaceuticals and Sanofi, have stressed that's the wholesale price and make a point of saying there will be programs to help people pay for it.

It's approved for people with atopic dermatitis, a catchall term for itchy skin caused by allergy.